

INFECTIOUS DISEASES II PANEL

Series Editors:

John E. Murphy, Pharm.D., FCCP, FASHP
Professor of Pharmacy Practice and Science
Associate Dean for Academic Affairs and Assessment
University of Arizona College of Pharmacy
Tucson, Arizona

Mary Wun-Len Lee, Pharm.D., FCCP, BCPS
Vice President and Chief Academic Officer
Pharmacy and Health Sciences Education
Midwestern University
Professor of Pharmacy Practice
Midwestern University
Chicago College of Pharmacy
Downers Grove, Illinois

Faculty Panel Chair

Ian R. McNicholl, Pharm.D., FCCP,
BCPS (AQ-ID), AAHIVP
Associate Director, Medical Affairs
Gilead Sciences
Foster City, California

ANTIMICROBIAL RESISTANCE

Authors

Kristi M. Kuper, Pharm.D., BCPS
GSPC Clinical Pharmacy Manager
VHA Performance Services
Houston, Texas

Amy N. Schilling, Pharm.D., BCPS
Clinical Pharmacist – Infectious
Diseases/Internal Medicine
Department of Pharmacy
Memorial Hermann The Woodlands
The Woodlands, Texas

Reviewers

Jessica Cottreau, Pharm.D., BCPS
Associate Professor
Rosalind Franklin University of Medicine and Science
Chicago, Illinois

Kimberli M. Burgner, MS, Pharm.D., BCPS
Division Director, Clinical Pharmacy Services
Parallon
Richmond, Virginia

INVASIVE FUNGAL INFECTIONS

Authors

Russell E. Lewis, Pharm.D., FCCP, BCPS (AQ-ID)
Associate Professor of Medicine, Infectious Diseases
Department of Medical and Surgical Sciences
Infectious Diseases Unit, Policlinico
S.Orsola-Malpighi,
Alma Mater Studiorum Università di Bologna
Bologna, Italy

Reviewers

Douglas Slain, Pharm.D., FCCP, BCPS (AQ-ID)
Associate Professor and Infectious
Diseases Clinical Specialist
Department of Clinical Pharmacy
West Virginia University
Morgantown, West Virginia

Nancy E. Flentge, Pharm.D., BCPS
Patient Care Pharmacist
Department of Pharmacy
Baylor Scott & White Continuing Care Hospital
Temple, Texas

TUBERCULOSIS

Author

Alexandria Garavaglia Wilson, Pharm.D., BCPS (AQ-ID)
Assistant Professor, Pharmacy Practice
Division of Specialty Care Pharmacy
Department of Pharmacy Practice
St. Louis College of Pharmacy
Clinical Pharmacist, Infectious Diseases
Division of Infectious Diseases
Department of Medicine
Washington University School of Medicine
Saint Louis, Missouri

Reviewers

Ian R. McNicholl, Pharm.D., FCCP,
BCPS (AQ-ID), AAHIVP
Associate Director, Medical Affairs
Gilead Sciences
Foster City, California

Becky S. Linn, Pharm.D., BCPS
Clinical Assistant Professor
Department of Pharmacy Practice
University of Wyoming School of Pharmacy
Laramie, Wyoming

Matthew F. Ambury, Pharm.D., BCPS
Assistant Director
Pharmacy Department – Lemuel Shattuck Hospital
Comprehensive Pharmacy Services
Jamaica Plain, Massachusetts

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Infectious Diseases II chapters:

Ralph H. Raasch, Pharm.D., BCPS
Associate Professor of Pharmacy (retired)
Division of Practice Advancement
and Clinical Education
Eshelman School of Pharmacy
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Marisel Segarra-Newnham, Pharm.D., MPH, FCCP,
BCPS
Clinical Pharmacy Specialist, Infectious Diseases
Pharmacy Service
Veterans Affairs Medical Center
West Palm Beach, Florida
Clinical Assistant Professor of Pharmacy Practice
University of Florida College of Pharmacy
Gainesville, Florida

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Craig R. Ballard (Janssen, ViiV Healthcare); Sandy Bartlett (Sunflower Developmental Solutions); David T. Bearden (Society of Infectious Diseases Pharmacists); Chi Duong (Warm Springs Health & Wellness Center); Sandy J. Estrada (Astellas); Monica V. Mahoney (Cubist Pharmaceuticals), (Forest Laboratories); Russell E. Lewis (Merck & Co., Inc.), (Gilead); Wilson O. Ly (Pacific AIDS Education Training Center); Christopher McCoy (Durata, Astra Zeneca);

Stock Ownership: Jennifer Cocohoba (Arena Pharmaceuticals [spouse or significant other]);

Royalties:

Grants: David T. Bearden (Cubist Pharmaceuticals); Elias B. Chahine (Cubist Pharmaceuticals, Inc.); Jennifer Cocohoba (National Institutes of Mental Health); Christopher R. Frei (Bristol-Myers Squibb [2 grants], Forest, Pfizer); Katie J. Suda (Intel Corporation); Christopher McCoy (Forest/Cerexa)

Honoraria: Craig R. Ballard (Janssen, Gilead Sciences, Merck, ViiV Healthcare, Simply Speaking HIV); Scott J. Bergman (Sanofi-Pasteur); P. Brandon Bookstaver (Merck and Co, Inc.); Elias B. Chahine (Cubist Pharmaceuticals, Inc., Forest Pharmaceuticals, Inc., Optimer Pharmaceuticals, Inc.); Sandy J. Estrada (Cubist); Lucas Hill (International Antiviral Society-USA); Vanthida Huang (Forest Pharmaceutical, Inc.); Wilson O. Ly (Gilead Sciences); Allana J. Sucher (AbbVie)

Other:

Nothing to Disclose: Matthew F. Ambury, Melissa Badowski, Kimberli M. Burgner, Jessica Cottreau, Paulina Deming, Eric A. Dietrich, Nancy E. Flentge, Alexandria Garavaglia-Wilson, Taylor K. Gill, Shellee A. Grim, Carol Heunisch, Shaun P. Keegan, Thomas J. Kleyn, Kristi M. Kuper, Becky S. Linn, Kim G. Luk, Kathleen A. Lusk, Michelle T. Martin, Kari A. McCracken, Ian R. McNicholl, April Miller Quidley, Carolyn Orendorff, Michael Ott, Jennifer Phillips, Abby Rivas Marrero, Amy N. Schilling, Douglas Slain, Inna S. Tsuker

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm.

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591
www.bpsweb.org